{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:54:45Z","timestamp":1783536885298,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dermatomyositis (DM) is characterized by activation of cytokine pathways that signal through the Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) axis, although the relative contribution of individual JAK family members remains unclear. Peripheral blood mononuclear cells were isolated from patients with active DM (n = 5), rheumatoid arthritis (RA, n = 7), systemic sclerosis (SSc, n = 7), and healthy donors (HD, n = 5). Phosphorylated STAT3 (pSTAT3) levels were assessed by flow cytometry in CD4+ and CD14+ cells under basal conditions and following selective inhibition of JAK1 (abrocitinib), JAK2 (gandotinib), JAK3 (decernotinib), or TYK2 (deucravacitinib). Under basal conditions, DM displayed the highest pSTAT3 levels in CD4+ cells (median 38.3%), significantly exceeding those observed in HDs (0.9%, P &amp;lt; 0.05) and SSc (8.6%, P &amp;lt; 0.05), while RA showed intermediate levels (17.7%). CD14+ cells from DM patients also demonstrated increased pSTAT3 compared with HDs (9.7% vs 1.4%, P &amp;lt; 0.05), without significant differences versus RA or SSc. Selective JAK inhibition revealed distinct disease-specific patterns. In DM, only TYK2 inhibition significantly reduced pSTAT3 levels in both CD4+ and CD14+ cells (P &amp;lt; 0.05), whereas in RA, pSTAT3 was modulated by inhibition of multiple JAK family members. No significant effects were observed in HDs or SSc patients. These findings identify a selective TYK2-dependent STAT3 activation signature in circulating immune cells from patients with DM, distinguishing this disease from other autoimmune conditions and supporting TYK2 as a potential therapeutic target in DM.<\/jats:p>","DOI":"10.1093\/cei\/uxag025","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:54:46Z","timestamp":1783511686000},"source":"Crossref","is-referenced-by-count":0,"title":["Dermatomyositis is characterized by TYK2-dependent STAT3 activation"],"prefix":"10.1093","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-7432","authenticated-orcid":false,"given":"M","family":"Fornaro","sequence":"first","affiliation":[{"name":"Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Del Vescovo","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-4462","authenticated-orcid":false,"given":"F","family":"Cacciapaglia","sequence":"additional","affiliation":[{"name":"Rheumatology Service, F. Miulli Hospital , Casamassima, Bari ,","place":["Italy"]},{"name":"Department of Medicine and Surgery, LUM University , Casamassima, Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8706-3386","authenticated-orcid":false,"given":"F","family":"Girolamo","sequence":"additional","affiliation":[{"name":"Unit of Human Anatomy and Histology, Department of Translational Biomedicine and Neuroscience \u2018DiBraiN\u2019, University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bizzoca","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Natuzzi","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Iannone","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070813372058900_uxag025-B1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: a systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2026070813372058900_uxag025-B2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1158768","article-title":"Targeting intracellular pathways in idiopathic inflammatory myopathies: a narrative review","volume":"10","author":"La Rocca","year":"2023","journal-title":"Front Med"},{"key":"2026070813372058900_uxag025-B3","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2026070813372058900_uxag025-B4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026070813372058900_uxag025-B5","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.3390\/jcm12206690","article-title":"Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib","volume":"12","author":"Harrington","year":"2023","journal-title":"J Clin Med"},{"key":"2026070813372058900_uxag025-B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","article-title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"6","author":"Sarabia","year":"2022","journal-title":"BMC Rheumatol"},{"key":"2026070813372058900_uxag025-B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108402","article-title":"Selective JAK1 inhibitors for the treatment of inflammatory bowel disease","volume":"245","author":"Nielsen","year":"2023","journal-title":"Pharmacol Ther"},{"key":"2026070813372058900_uxag025-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2024.104951","article-title":"Modulation of IL-6 receptor\/STAT3 downstream signaling in rheumatoid arthritis patients","volume":"141","author":"Cacciapaglia","year":"2025","journal-title":"Exp Mol Pathol"},{"key":"2026070813372058900_uxag025-B9","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026070813372058900_uxag025-B10","first-page":"vi5","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51 Suppl 6","author":"Kay","year":"2012","journal-title":"Rheumatol. Oxf. Engl"},{"key":"2026070813372058900_uxag025-B11","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026070813372058900_uxag025-B12","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070813372058900_uxag025-B13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis disease area and severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026070813372058900_uxag025-B14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026070813372058900_uxag025-B15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2133.2004.06144.x","article-title":"Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis","volume":"151","author":"Caproni","year":"2004","journal-title":"Br J Dermatol"},{"key":"2026070813372058900_uxag025-B16","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","article-title":"Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis","volume":"141","author":"Patel","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2026070813372058900_uxag025-B17","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217240","article-title":"Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies","volume":"15","author":"Argyriou","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026070813372058900_uxag025-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4331\/wjbc.v13.i1.1","article-title":"Current understanding of the role of tyrosine kinase 2 signaling in immune responses","volume":"13","author":"Muromoto","year":"2022","journal-title":"World J Biol Chem"},{"key":"2026070813372058900_uxag025-B19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2010.517215","article-title":"Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis","volume":"40","author":"Shen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"2026070813372058900_uxag025-B20","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1038\/s41598-018-23539-4","article-title":"Interleukin-23 as a therapeutic target for inflammatory myopathy","volume":"8","author":"Umezawa","year":"2018","journal-title":"Sci Rep"},{"key":"2026070813372058900_uxag025-B21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"2026070813372058900_uxag025-B22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4081\/reumatismo.2014.746","article-title":"Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies","volume":"66","author":"Notarnicola","year":"2014","journal-title":"Reumatismo"},{"key":"2026070813372058900_uxag025-B23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/mr\/roac147","article-title":"Increased expression of the p-STAT3\/IL-17 signaling pathway in patients with dermatomyositis","volume":"34","author":"Li","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026070813372058900_uxag025-B24","doi-asserted-by":"publisher","volume-title":"A Phase 3 Trial of Brepocitinib in Dermatomyositis","author":"Vleugels RA, Paik JJ, Bauer Ventura I, Mangold AR, Gandiga PC, Haemel A, et al.","DOI":"10.1056\/NEJMoa2503531"},{"key":"2026070813372058900_uxag025-B25","article-title":"Brepocitinib inhibits key pathogenic cytokine signaling in dermatomyositis patients [abstract]","volume":"77","author":"Charles-Schoeman","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag025\/68721539\/uxag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag025\/68721539\/uxag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:37:33Z","timestamp":1783532253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxag025\/8728467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxag025","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"uxag025"}}